EHS
EHS

Dynacure secures $55 million Series A round for rare genetic disease treatment

French firm to start trial of Dyn101, in-licensed from US-based Ionis Pharmaceuticals, in centronuclear myopathy next year.

EHS

Leave a Reply

Your email address will not be published.

Back to top button